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53 is a transcription factor that induces growth arrest
or apoptosis in response to cellular stress. To identify
new p53-inducible proapoptotic genes, we compared,
by differential display, the expression of genes in spleen or
thymus of normal and p53 nullizygote mice after 
 
 
 
-irradiation
of whole animals. We report the identiﬁcation and charac-
 
terization of human and mouse 
 
Scotin
 
 homologues, a novel
gene directly transactivated by p53. The Scotin protein is
p
 
localized to the ER and the nuclear membrane. Scotin can
induce apoptosis in a caspase-dependent manner. Inhibition
of endogenous Scotin expression increases resistance to
p53-dependent apoptosis induced by DNA damage, sug-
gesting that Scotin plays a role in p53-dependent apoptosis.
The discovery of Scotin brings to light a role of the ER in
p53-dependent apoptosis.
 
Introduction
 
Mutations that inactivate the p53 tumor suppressor protein
are the most common genetic aberrations known to occur in
human cancers. The best described biological functions of
p53 are the induction of cell cycle arrest and apoptosis in
response to cellular stresses (May and May, 1999; Oren,
1999; Vogelstein et al., 2000). Therefore, p53 prevents
damaged cells from proliferating and thus protects against
neoplastic transformation. Thus, p53 functions as a “guardian
of the genome” (Lane, 1992).
p53 can act as a transcription factor that, in response to
cellular stress, binds DNA in a sequence-specific manner
and induces the expression of genes containing a p53 binding-
site element in their promoter or introns (El-Deiry et al.,
1992; Funk et al., 1992; Bourdon et al., 1997). Only a few
genes have been shown to be directly transactivated, in
vivo, by wild-type (wt)* p53 after cellular stress. Identification
of transcriptional targets of p53 is critical in discerning
pathways by which p53 affects global cellular outcomes
such as growth arrest and cell death. The identification of the
 
cyclin-dependent kinase inhibitor 
 
WAF1
 
 as a p53-responsive
gene helps to explain how p53 can induce cell cycle arrest. In
contrast, the biochemical basis of p53-dependent apoptosis is
still unclear. Depending on the experimental models used, p53
transcriptional activity has been reported to be required
(Attardi et al., 1996; Yonish-Rouach et al., 1996; Jimenez et
al., 2000) or dispensable (Caelles et al., 1994; Haupt et al.,
1995) for p53-dependent apoptosis. Recently, several p53-
inducible  genes have been identified that encode proteins
with apoptotic potential (Bax, CD95/Fas, Noxa, Pidd,
P53AIP, and PUMA) (Miyashita and Reed, 1995; Muller et
al., 1998; Lin et al., 2000; Munsch et al., 2000; Nakano and
Vousden, 2001; E. Oda et al., 2000; K. Oda et al., 2000; Yu et
al., 2001). However, it remains to be seen whether one or a
subset of the newly identified genes play a key role in p53-
dependent apoptosis.
To increase the likelihood of identifying new proapoptotic
genes induced by p53 under physiological conditions, we used
the normal and p53 nullizygote (p53
 
 
 
/
 
 
 
) mouse model as a
source of differentially expressed mRNA. We report here the
identification and characterization of the mouse and the human
 
Scotin
 
 gene, a novel p53-inducible proapoptotic gene.
 
Results
 
Isolation of a novel p53-regulated gene 
by differential display
 
Previous studies have shown that cells from thymus or spleen
 
undergo massive p53-dependent apoptosis after 
 
 
 
-irradiation
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in normal mice but not in p53
 
 
 
/
 
 
 
 mice (Clarke et al., 1993;
Lowe et al., 1993). Therefore, this model can be used to iden-
tify proapoptotic genes induced by p53, in vivo, after 
 
 
 
-irradi-
ation of the entire animal instead of cellular models. Cellular
models are generally established from tumor or immortalized
cells that might have lost or reduced proapoptotic gene ex-
pression as an adaptation to in vitro culture. Hence, we have
compared by differential display the expression of genes in the
spleen or thymus of homozygote (p53
 
 
 
/
 
 
 
) and p53 nullizy-
gote (p53
 
 
 
/
 
 
 
) mice after 
 
 
 
-irradiation of whole animals.
Two female mice, one p53
 
 
 
/
 
 
 
 and the other p53
 
 
 
/
 
 
 
 from
the same litter (6 wk old), were 
 
 
 
-irradiated for 1 min at a
dose of 5 Gy/min. The spleen and thymus were removed 3 h
after irradiation. After total RNA extraction from spleens,
we compared by a differential display method (Liang and
Pardee, 1992; Zhao et al., 1996) only expression of RNA
from p53
 
 
 
/
 
 
 
 and p53
 
 
 
/
 
 
 
 irradiated mice to identify genes
specifically induced by p53 in response to irradiation. The
screening resulted in the isolation of 112 differentially ex-
pressed DNA fragments. 46 fragments among the most dif-
ferentially expressed were cloned and sequenced. Most se-
quences did not correspond to previously identified genes.
 
We analyzed the levels of 10 of the most differentially ex-
pressed mRNAs by Northern blot and semi-quantitative
RT-PCR to confirm differential expression, comparing lev-
els after irradiation in spleens from normal or p53
 
 
 
/
 
 
 
mouse. The mRNA corresponding to clone 105.9 displayed
stronger and more consistent expression after ionizing radia-
tion in the wt mouse than in p53
 
 
 
/
 
 
 
 mouse (Fig. 1, A and
B), suggesting that the differential expression was p53-
dependent. Therefore, clone 105.9 was chosen for further
study and was named 
 
Scotin
 
.
To confirm the in vivo differential expression of 
 
Scotin
 
mRNA, we performed an in situ hybridization analysis (Fig.
1 C). Spleens and thymus were resected after irradiation
along with the same organs from nonirradiated mice of the
same genotype as controls. Cryosections of spleen and thy-
mus were hybridized with an antisense (AS) digoxigenin-
labeled 
 
Scotin
 
 RNA probe. Fig. 1 C shows that 
 
Scotin
 
 mRNA
was strongly induced only in the spleen and in the thymus of
irradiated wt mice. No induction of 
 
Scotin
 
 mRNA could be
detected in the spleen or thymus of p53
 
 
 
/
 
 
 
 mice after 
 
 
 
-irra-
diation. Hybridization with the sense digoxigenin-labeled
 
Scotin
 
 RNA probe performed in the same conditions gave
Figure 1. Scotin mRNA is induced 
after  -irradiation in the spleen and 
thymus of normal mouse but not in 
p53
 /  mouse. p53 nullizygote (
 / ) 
mice as well as wt (p53
 / ) litter mates 
were exposed to 5 Gy  -irradiation. 
Total RNA was extracted 3 h later from 
the spleen of each mouse. (A) Northern 
blot. 10  g of total RNA was analyzed 
by hybridization with a mouse Scotin 
probe. After autoradiography, the blot 
was stripped and rehybridized with rat 
GAPDH probe. (B) Semi-quantitative 
RT-PCR. 0.5  g of total RNA was 
analyzed by RT-PCR by incorporating 
[
33P]dATP and using Scotin- or GAPDH-
specific primers as described in Materials 
and methods. PCR reactions were 
stopped after different cycles to assess the 
linear amplification. PCR products were 
electrophoresed on 8% polyacrylamide 
gel before autoradiography. (C) In situ 
hybridization. Two p53
 /  male mice 
and two p53
 /  male mice were exposed 
to 5Gy of whole body  -irradiation. 
Spleen and thymus were removed 3 h 
after irradiation. Sections were incubated 
with a digoxigenin-labeled antisense 
(AS) Scotin RNA probe or with a 
digoxigenin-labeled sense (S) Scotin 
RNA probe. Sections were incubated 
with antidigoxigenin antibody conjugated 
to alkaline phosphatase. Scotin mRNA 
was then visualized by the addition of a 
precipitating substrate (NBT/BCIP). 
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no signal, confirming that the in situ hybridization was spe-
cific for 
 
Scotin
 
 mRNA. Together, these results indicate that
 
Scotin
 
 gene expression is induced, in vivo
 
,
 
 in a p53-depen-
dent manner in response to ionizing radiation.
 
Scotin
 
 gene is directly transactivated by p53
 
Using a genome walking kit PCR, we isolated a fragment of
2,980 bp corresponding to the mouse 
 
Scotin
 
 promoter. On
the basis of the statistics of known p53 target genes and us-
ing a computer approach (Bourdon et al., 1997), we identi-
fied a potential p53-responsive element composed of nine
decamers located between positions 768 and 592 (Fig. 2 A)
in the mouse 
 
Scotin
 
 promoter. We performed electro-
phoretic mobility shift assay (EMSA) to examine whether
p53 could bind a double-stranded oligonucleotide corre-
sponding to the core (Fig. 2 A, S1) of the putative p53-
binding site from the 
 
Scotin
 
 promoter. We observed a mo-
bility shift when purified wt p53 was incubated with the
S1-binding site. Moreover, addition of an anti-p53 anti-
body (pAb 421) to the reaction mixture induced a super-
shift, confirming the presence of p53 in the protein–DNA
complex (Fig. 2 B). To assess the specificity of binding of
p53 to the S1-binding site, we added to the reaction mix-
ture 50-fold molar excess of unlabeled wt S1-binding site or
of unlabeled mutant S1-binding site. The S1 mutant-bind-
ing site is mutated only in one decamer, leaving the other
one intact. The unlabeled wt S1-binding site, but not the
mutant S1-binding site, efficiently competed with the for-
mation of the electrophoretically retarded p53–DNA com-
plex, confirming the specificity of p53 binding to the S1
site from the 
 
Scotin
 
 promoter (Fig. 2 B).
We further examined whether p53 could transactivate the
 
Scotin
 
 promoter. The genomic fragment corresponding to
the mouse 
 
Scotin
 
 promoter was subcloned upstream of the
luciferase reporter gene to generate the Scotluc reporter plas-
mid. Cotransfection of different amounts of human wt p53
Figure 2. Scotin gene is directly 
transactivated by p53. (A) A potential 
p53-binding site was identified in the 
promoter of the Scotin gene. Nine 
decamers containing no more than 
three disparities compared with the 
consensus sequence (RRRCWWGYYY) 
were identified according to our previous 
analysis of known p53-binding sites 
(Bourdon et al., 1997). (R   G or A, 
W   T or A, Y   C or T). The boxed 
sequence (S1) indicates the pair of 
decamers with a minimal space 
between both decamers and containing 
the smallest number of disparities with 
the consensus sequence. The S1 
oligonucleotide was studied by EMSA. 
The asterisk indicates the disparities 
with the consensus sequence. (B) p53 
binding to the DNA element (S1) from 
the Scotin promoter. EMSA of double-
stranded oligonucleotides. Equal 
amounts of 
32P-labeled oligonucleotide 
S1 (130 fmol) were incubated with the 
purified baculovirus–produced wt 
human p53 (400 fmol). In the designated 
lanes, the p53 antibody pAb 421 (0.3  g) 
was included. For competition assays, 
the unlabeled wt S1 oligonucleotides 
(50-fold molar excess), or the mutant 
(mut) S1 oligonucleotides (50-fold molar 
excess) were added to the reaction. 
(C) The Scotin promoter is induced by 
p53 in a dose-dependent manner. The 
entire Scotin promoter was subcloned 
upstream of the luciferase reporter gene 
in the promoter-less plasmid pGL3 basic. The plasmid PG13-Luc containing the luciferase reporter gene driven by a p53-responsive 
promoter was used as a positive control for p53 transcriptional activity. H1299 cells were cotransfected with the indicated reporter plasmid 
(1  g/ml), a trace amount of pSVrenilla (0.02  g/ml) as an internal control, and an increasing concentration of p53 expression vector 
driven by SV-40 early promoter (SVp53). (D) The wt p53-binding site from the Scotin promoter confers p53 responsiveness to a minimal 
heterologous promoter. A fragment of 760 bp containing the entire p53-binding site from the Scotin promoter was subcloned upstream of 
a minimal promoter fused to the luciferase reporter gene (Scot-Adluc). The minimal promoter derives from the adenovirus major late 
promoter, which is not responsive to p53. The S1 p53-binding site was mutated in 1 bp of one decamer by point mutagenesis PCR to 
generate Mut–Adluc plasmid as described in Materials and methods. H1299 cells were cotransfected with the indicated reporter plasmid 
(3  g/ml), a trace amount of pSVrenilla (0.02  g/ml) as an internal control, and an increasing concentration of p53 expression vector 
driven by SV-40 early promoter (SVp53). In reporter assays, the amount of SV-40 promoter was maintained constant at 0.7  g/ml in each 
transfection by adding empty SV-40 expression vector. Luciferase activity was normalized to Renilla activity. Results shown are the 
average of four independent experiments performed in triplicate. SDs are indicated as error bars. 
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expression vector with the Scotluc plasmid into H1299 cells
resulted in a significant increase in reporter luciferase activity
in a p53 dose-dependent manner. As a positive control, we
cotransfected into H1299 cells different amounts of human
wt p53 expression vector with the PG13-luciferase reporter
plasmid, which contains a synthetic p53 binding element.
The 
 
Scotin
 
 promoter and PG13 promoter have a comparable
responsiveness to p53 (Fig. 2 C).
To determine whether the S1 p53-binding site contained
in the 
 
Scotin
 
 promoter can confer responsiveness to p53, the
760-bp fragment containing the entire wt p53-binding site
was subcloned upstream from a minimal promoter, which
drives the luciferase gene (AdLuc). As a control, the 760-bp
fragment mutated only in 1 bp of the S1 p53-binding site
was subcloned into the AdLuc plasmid. After transfection
with various amounts of p53 expression vector, only the in-
sert containing the wt p53-binding site confers responsive-
ness to p53 in a dose-dependent manner to a minimal pro-
moter (Fig. 2 D). The 
 
Scotin
 
 gene is therefore a bona fide
direct target of p53.
 
Scotin is conserved between mouse and human
 
We designed primers from the short sequence correspond-
ing to the 3
 
 
 
end of mouse 
 
Scotin
 
 mRNA and performed a
5
 
 
 
/3
 
 
 
 rapid amplification of cDNA ends (RACE) PCR on
mRNA extracted from thymus of irradiated p53
 
 
 
/
 
 
 
 mice.
We obtained a sequence of 1,850 bp, which is consistent
with the apparent size of 
 
Scotin
 
 mRNA observed in North-
ern blots. The ORF predicts a protein of 235 amino acid
residues, containing in the NH
 
2
 
 terminus a putative signal
sequence of 22 residues, and in the central part a putative
transmembrane domain composed of 18 hydrophobic
amino acids immediately followed by a domain rich in pro-
lines. No further protein domain homologies to any known
gene product have been identified. The presence of an in-
frame stop codon within the 5
 
  
 
untranslated region (UTR)
supports the correct assignment of the first methionine of
the ORF. (Fig. 3 A).
To obtain human 
 
Scotin
 
 cDNA, we searched in GenBank
for human EST sequences homologous to mouse 
 
Scotin
 
cDNA. We designed primers from the longest human 
 
Sco-
tin
 
 EST sequence and performed a 5
 
 
 
/3
 
 
 
 RACE PCR on
mRNA from human placenta. We obtained a complete
cDNA with the apparent size of 2.2 kb. It contains one
ORF and a relatively long 3
 
 
 
 UTR. The ORF predicts a
protein of 240 amino acid residues sharing 72% homology
(70% identity) with the mouse Scotin protein. Alignment
of mouse and human Scotin protein shows that the signal
sequence, the cysteines in the NH
 
2
 
 terminus, the trans-
membrane domain, and the proline/tyrosine domains are
well conserved (Fig. 3 B).
We searched for the human 
 
Scotin
 
 gene in the human
draft genome database. The 
 
Scotin
 
 gene is composed of six
exons and maps to the chromosome 3p21.3, which is a very
frequent breakpoint in many cancers (GenBank/EMBL/
DDBJ accession no. AC104448). We also identified a 
 
Scotin
 
pseudogene localized on chromosome Xq13.1–13.3 (Gen-
Bank/EMBL/DDBS accession no. AL139400). By RT-
PCR, we could not detect transcripts expressed from the
 
Scotin
 
 pseudogene.
Scotin protein expression is induced in a 
p53-dependent manner in response to cellular stress
Two affinity-purified rabbit pAbs (M105 and H105) were
raised against a peptide corresponding to the COOH termi-
nus of mouse or human Scotin protein, respectively. Their
specificity was assessed by Western blot analysis on protein
extracts from H1299 cells transfected with mouse or human
Scotin expression vectors. Mouse and human anti-Scotin an-
tibody detected only one protein with an apparent size of 25
kD, which is consistent with the expected size for Scotin
(unpublished data).
To further characterize Scotin protein, it was essential to
identify cell lines that could induce Scotin upon DNA
damage. We treated primary mouse embryonic fibroblasts
(MEF) from p53
 /  and p53
 /  littermate mice or human
primary fibroblast (MRC5) and several p53 positive or nega-
tive human tumors cell lines with UV-C light or with acti-
nomycin D (60 ng/ml), a DNA intercalator. Actinomycin D
used at 60 ng/ml does not prevent RNA polymerase II activ-
ity, but is a potent activator of p53 (Blattner et al., 1999;
Nakano and Vousden, 2001). Proteins were extracted after
treatment and analyzed by Western blot. Waf and p53 pro-
tein levels were used as an indication of p53 activation. Sco-
tin protein clearly accumulates after UV irradiation or acti-
nomycin D treatment in mouse p53
 /  MEF, human
primary fibroblast, and human tumor cells expressing wt
p53, but not in mouse p53
 /  MEF or human tumor cell
lines devoid of p53 expression (Fig. 4, A and B).
To determine whether p53 expression is sufficient to
induce Scotin expression, we used human p53-null cells
(H1299 and Saos-2) that contain stable integrated p53
cDNA inducible by tetracycline. In both cell lines, Scotin was
induced after the induction of wt p53, whereas no Scotin in-
duction could be detected in the control mutant p53His169-
tetracycline inducible Saos-2 cells (Fig. 4 C), indicating that
Figure 3. Scotin is a putative transmembrane protein. (A) Diagram 
representing the primary structure of Scotin protein. (B) Human and 
mouse Scotin protein alignment, hydrophobic domain in solid box, 
and putative signal sequences in hashed box.Scotin, a p53-inducible gene, promotes apoptosis | Bourdon et al. 239
wt p53 is necessary and sufficient to induce Scotin. However,
Scotin induction is slower in such cell lines compared with
induction after cellular stress, suggesting that cellular stress
and p53 may act in synergy to induce Scotin.
Scotin protein is localized in the ER 
and the nuclear membrane
After exposure to UV-C irradiation, p53
 /  MEF were
stained for Scotin using anti–mouse Scotin antibody. A
bright ring around the nucleus was observed in cells treated
with UV but not in control cells (Fig. 5, a and b). Similar lo-
calization was observed in mouse NIH3T3 fibroblast and in
human MCF7 cells (unpublished data). To determine the
subcellular localization of endogenous Scotin protein, we
treated MCF 7 cells with actinomycin D and costained
them for human Scotin and human gp96/GRP94 protein.
gp96 is a chaperone protein predominantly expressed in the
ER (Koch et al., 1986; Li and Srivastava, 1993). As shown
by confocal microscopy, gp96 and Scotin were colocalized in
the ER after cellular stress (Fig. 5, c–e).
Because we planned to express Scotin by transient trans-
fection to study its biological activity, it was essential to de-
termine whether the subcellular localization of ectopic Sco-
tin was identical to the endogenous. Human H1299 cells
were transiently transfected with mouse Scotin expression
vector. To mimic physiological expression levels as closely as
possible, we used Scotin expression vectors driven either by
the SV-40 promoter or the weak minimal major late pro-
moter from adenovirus (Ad). A bright ring around the nu-
cleus was observed in H1299 cells transfected with AdScotin
Figure 4. Scotin protein expression is 
induced in a p53-dependent manner. 
(A) Primary MEF expressing wtp53 
induce Scotin after UV irradiation or 
Actinomycin D treatment. MEF (passage 2) 
from p53
 /  and p53
 /  littermate mice 
were exposed to UV-C light (20 J/m
2) or 
Actinomycin D (60 ng/ml), a potent p53 
activator. Proteins were extracted at the 
indicated time after treatment and 
analyzed by Western blot. (B) Primary 
human fibroblasts and human tumor cell 
lines expressing functional p53 induce 
Scotin in response to Actinomycin D. 
The primary human fibroblast MRC5, 
the tumor cell lines (MCF7 and U2OS) 
expressing functional p53, and the tumor 
cell lines devoid of p53 expression 
(Saos-2 and H1299) were treated with 
60 ng/ml of Actinomycin D. Proteins 
were extracted at the indicated time and 
analyzed by Western blot. (C) p53 
expression is sufficient to induce human 
Scotin expression. Proteins were 
extracted at the indicated time after 
tetracycline induction from tetracycline-
inducible p53 H1299 cells or Saos-2 cell 
lines described in Materials and methods. 
Membranes were probed in succession 
using anti-Scotin pAb, anti-p53 pAb, and 
anti-Waf mAb, as described in Materials 
and methods. To control loading and 
transfer efficiency, membranes were 
incubated with antiactin mAb.240 The Journal of Cell Biology | Volume 158, Number 2, 2002
vector. (Fig. 5 f). We observed the same staining pattern af-
ter transient transfection in Saos-2 and NIH3T3 cell lines
(unpublished data). Moreover, as judged by immunostain-
ing, transfection of AdScotin plasmid did not give rise, at
the cellular level, to a strong overexpression of Scotin.
Transfection of SVScotin vector gave rise to a stronger over-
Figure 5. Mouse and human Scotin proteins are located in the ER and the nuclear envelope. (a and b) MEF were incubated in the presence 
or absence of 60 ng/ml of actinomycin D and stained by indirect fluorescence (FITC) using anti–mouse Scotin antibody (a) nontreated MEF, 
and (b) treated MEF. (c–e) MCF7 cells treated with 60 ng/ml of actinomycin D were costained by indirect fluorescence for endogenous Scotin 
protein using (c) anti–human Scotin antibody (FITC) and (d) the monoclonal anti-gp96 antibody (Texas red); (e) merge. gp96/GRP94 is a 
chaperone protein exclusively located in the ER. (f and g) Immunostaining of H1299 cells transfected with mouse Scotin expression vectors, 
(f) 5  g of AdScotin, (g) 10  g of SVScotin, and stained by indirect fluorescence (FITC) using anti–mouse Scotin antibody. (h–j) Scotin is 
colocalized with gp96 in the ER and the nuclear membrane after ectopic expression. H1299 cells transfected with 10  g of SVScotin 
expression vector were costained by indirect fluorescence (h) using rabbit polyclonal anti–mouse Scotin antibody (FITC) and (i) mouse 
monoclonal anti-gp96 antibody (Texas red); (j) merge. (k–m) Scotin and mitochondria have distinct staining patterns. H1299 cells transfected 
with 5  g of SVScotin expression vector were costained by indirect fluorescence using (k) anti–mouse Scotin antibody (FITC) and (l) red 
MitoTracker
® (red); (m) merge. Bars, 5  m.Scotin, a p53-inducible gene, promotes apoptosis | Bourdon et al. 241
expression of Scotin in H1299 cells, revealing the character-
istic staining pattern of the ER and of the nuclear membrane
(Fig. 5 g). To assess the localization of Scotin protein after
transfection, we costained H1299-transfected cells for Sco-
tin and gp96 or mitochondria. As shown by confocal mi-
croscopy, the Scotin and gp96 proteins were colocalized,
confirming that Scotin protein is localized in the ER and in
the nuclear membrane after transfection (Fig. 5, h–j). How-
ever, the Scotin staining pattern is different from the mito-
chondria staining pattern (Fig. 5, compare k with l and m
[merge]). Together, these results indicate that Scotin protein
is mainly located in the ER and can be located in the nuclear
membrane in cells overexpressing Scotin after transfection.
Scotin can promote apoptosis independently of p53
We noticed that induction of Scotin protein was coincident
with cell death in cell lines expressing wt p53 after treatment
with UV or actinomycin D. Moreover, no stable clone over-
expressing wt Scotin could be obtained in H1299 and Saos-2
cells (cell lines devoid of p53) after cotransfection of a vector
expressing the neomycin resistance gene with AdScotin or
SVScotin vectors (unpublished data), suggesting that Scotin
protein might prevent cell proliferation.
The ER can trigger cell signals leading to apoptosis in re-
sponse to stresses (ER stress) that impair its functions, such
as protein overexpression after transfection, misfolded pro-
tein, hypoxia, inhibition of glycosylation, and disruption of
the ER calcium store (for review see Kaufman, 1999). Be-
cause Scotin is localized in the ER, it was essential to deter-
mine whether the cytotoxic effect of the Scotin protein was
due to an intrinsic activity or due to an artifact of overexpres-
sion after transfection. To examine this, we constructed three
different Scotin mutant proteins by deleting large regions of
Scotin protein (Fig. 6 A). Because the  pro Scotin mutant
lost the epitope for the anti-Scotin antibody, all mutants and
wt Scotin proteins were fused at the COOH-terminal end to
the FLAG peptide. H1299 cells were transiently transfected
with wt Scotin-FLAG expression vectors driven by SV-40 or
Ad promoters (Fig. 6 A). Anti-FLAG and anti-Scotin anti-
bodies gave identical patterns of staining, indicating that the
Figure 6. wt Scotin protein has an 
intrinsic proapoptotic activity. 
(A) Schematic representation of the Scotin 
mutants. (B) Scotin mutants deleted of 
the NH2 terminus are located in the ER. 
H1299 cells were transfected with 0.5  g 
of AdScotin-FLAG (a), or SVScotin-FLAG 
(b), or Ad Cys (c, or Ad N (d), or SV  
pro (e). Cells were stained with anti-FLAG 
(M2) mouse mAb followed by anti–mouse 
antibody conjugated to FITC. Bars, 5  m. 
(C) wt Scotin protein induces apoptosis 
after transfection. The DNA content of 
each transfected population was 
determined by flow cytometry analysis. 
The percentage of sub-G1 DNA content 
represents the percentage of apoptotic 
cells 48 h after transfection. H1299 cells 
transfected with the following different 
expression vectors: 5  g/ml AdCAT, or 
10  g/ml SVScotin, or 5  g/ml AdScotin, 
or 2  g/ml SVp53, or 5  g/ml Ad Cys, 
or 5  g/ml Ad N. Histogram represents 
the average of at least three independent 
transfections. SDs are reported as error 
bars. (D) Scotin-mediated apoptosis is 
inhibited by caspase inhibitor. The DNA 
content of each transfected population 
was determined by flow cytometry 
analysis. H1299 cells transfected with 5 
 g/ml of AdCAT, 5  g/ml of SVScotin-
FLAG, or 5  g/ml of AdScotin-FLAG 
were incubated in presence or absence 
of the caspase inhibitor Z-VAD-FMK. 
Histogram represents the average of at 
least three independent transfections. 
SDs are reported as error bars. (E) Scotin 
induces caspase-3 activation. The 
caspase-3 activity was determined using 
the Colorimetric Caspase-3 Cellular 
Activity Assay kit. The H1299 cells 
were transfected with 5  g/ml of AdCAT, 
5  g/ml of AdScotin-FLAG, or 2  g/ml of 
SVp53 expression vectors. As indicated, cells were incubated in the presence or absence of the caspase inhibitor Z-VAD-FMK. Histogram 
represents the average of three independent transfections. SDs are reported as error bars.242 The Journal of Cell Biology | Volume 158, Number 2, 2002
subcellular localization of Scotin was not affected by the
FLAG fusion. After transfection of H1299 cells with mutant
or wt Scotin vectors, cells were stained by anti-FLAG anti-
body. The localization of the  Cys Scotin mutant protein
was similar to that of the wt Scotin protein (Fig. 6 B, com-
pare c with a). The immunostaining pattern of the  N Sco-
tin was similar to the immunostaining pattern obtained after
transfection of wt Scotin expressed under the SV-40 pro-
moter (Fig. 6 B, compare d with b), probably because the
 N Scotin mutant was expressed at a comparable level. The
results indicate that the subcellular localization of  N Sco-
tin,  Cys Scotin, and wt Scotin protein is similar and that
the cysteine domain of Scotin is not required for the localiza-
tion to the ER. The immunostaining pattern of the  pro
Scotin mutant protein is different from the immunostaining
pattern observed with wt Scotin protein (Fig. 6 B, compare e
with b), indicating that the proline-rich domain is required
for the ER localization. We have not studied further the
 pro Scotin mutant because it was impossible to determine
whether the lack of cytotoxicity of this mutant (unpublished
data) was due to the loss of the ER localization or due to the
deletion (100 aa) of an active domain.
To investigate the Scotin-mediated cell death, we per-
formed a flow cytometry analysis as previously described to
quantify apoptosis induced by p53 (Yonish-Rouach et al.,
1994; Haupt et al., 1995; Deguin-Chambon et al., 2000).
H1299 cells were transiently transfected with wt or mutant
Scotin-FLAG expression vectors. The results of three inde-
pendent experiments are presented Fig. 6 C. Transient
transfection of SVp53 expression vector caused 16% of
transfected cells to have a sub-G1 DNA content, which is
indicative of apoptotic cells, in agreement with earlier re-
ports (Yonish-Rouach et al., 1994; Haupt et al., 1995). The
Scotin-expressing cells transfected with plasmid SVScotin-
FLAG or AdScotin-FLAG also exhibited a significantly high
fraction of cells with sub-G1 DNA content (16 and 12%,
respectively). In contrast, only 4.5% of the total  Cys or
 N Scotin mutant–expressing cells contained a sub-G1
DNA content. This indicates that both truncated Scotin
mutant proteins have lost most of the apoptotic activity.
Therefore, Scotin-mediated cell death is due to an intrinsic
activity and not due to disruption of the ER functions after
overexpression of an ER-located protein.
Scotin-mediated cell death was inhibited when H1299
cells were incubated with the caspase inhibitor zVAD before
transfection (Fig. 6 D). To determine whether Scotin could
promote caspase 3 activation, Scotin expression vector was
transfected into H1299 cells. Transfection of wt p53 or
CAT expression vector into H1299 cells was used as positive
and negative controls, respectively. Only Scotin and p53 in-
duced caspase activation as assessed by caspase3 cellular ac-
tivity assay. No caspase activity could be detected upon
transfection of AdCAT vector (Fig. 6 E). This indicates that
Scotin can induce apoptosis in a caspase-dependent manner.
Scotin protein is involved in apoptosis induced 
by DNA damage
To assess the role of Scotin in apoptosis under physiological
conditions, NIH3T3 cells were stably transfected with an
AS Scotin expression vector. As a control, NIH3T3 cells
were stably transfected with pcDNA3 expression vector ex-
pressing a noncoding sequence unrelated to Scotin or other
known genes. After selection in the presence of neomycin,
the pooled populations of transfectant expressing the control
or the Scotin AS vector were exposed to actinomycin D (60
ng/ml). Scotin protein level was analyzed by Western blot
(Fig. 7 A). Scotin basal level was detectable and well-induced
after treatment in control AS-expressing cells. However,
Scotin was barely detectable in Scotin antisense-expressing
cells (Scotin-AS) despite a strong activation of p53 after acti-
nomycin D treatment. This indicates that Scotin AS expres-
sion vector strongly inhibited endogenous Scotin expression.
To determine if Scotin plays a role in the p53-dependent
apoptosis induced by DNA damage, we treated with UVC
(15 J/m
2) the pooled populations expressing the control or
the Scotin AS vector. The percentage of cell survival was de-
termined by trypan blue exclusion analysis (Fig. 7 B). The
Figure 7. Scotin is involved in p53-dependent apoptosis.
(A) Endogenous Scotin expression is inhibited in cells stably transfected 
with Scotin AS vector. 3T3 cells stably transfected with control 
antisense (AS) expression vector and 3T3 cells stably transfected with 
Scotin antisense (Scotin-AS) expression vectors were treated with 
actinomycin D (60 ng/ml). Proteins were extracted at the indicated 
time and analyzed by Western blot. Scotin expression was detected 
by using anti–mouse Scotin antibody. As a positive control, p53 
induction was determined using CM5 anti–mouse p53 antibody. 
Protein loading was controlled by antiactin antibody. (B) Cells 
expressing a low level of Scotin protein are resistant to DNA damage. 
For the trypan blue exclusion assay, Scotin-AS cells ( ) or AS cells 
( ) were irradiated by UV-C (15 J/m
2) and harvested at the indicated 
times. Viable cells were determined by trypan blue exclusion and 
counted using a hemocytometer. The percentage of cell survival 
was calculated as the number of viable cells in relation to the 
number of cells plated at the start of the trial. Each point is the 
average of at least three experiments. SDs are reported as error bars.Scotin, a p53-inducible gene, promotes apoptosis | Bourdon et al. 243
DNA damage–mediated apoptosis is strongly impaired, but
not abolished, by the inhibition of Scotin expression. This
indicates that Scotin plays a role in the p53-dependent
apoptosis under physiological conditions but, as previously
reported for Noxa and PUMA (E. Oda et al., 2000; Nakano
and Vousden, 2001), other proapoptotic genes might also be
activated.
Discussion
Few proapoptotic genes directly induced, in vivo, by p53
have been described. This is probably due to the use of cellu-
lar p53 models, which being derived from tumors or immor-
talized primary cells, are likely to have lost some proapoptotic
gene expressions as an adaptation to in vitro culture. It has
been shown that thymus and spleen cells undergo a massive
p53-dependent apoptosis after ionizing radiation in normal,
but not in p53
 / , mice (Clarke et al., 1993; Lowe et al.,
1993). This animal model can thus be used to identify new
genes involved in p53-dependent apoptosis induced by irra-
diation. In the present study, we report the identification and
characterization of mouse and human homologues of a novel
gene, named Scotin. The Scotin gene is induced, in vivo, after
ionizing radiation in a p53-dependent manner. p53 binds
specifically to a p53-binding site contained in the Scotin gene
promoter and directly transactivates the Scotin gene. By
Western blot, we showed that human and mouse Scotin pro-
teins are induced in a p53-dependent manner in response to
DNA damage in primary and tumor cell lines. By using a tet-
racycline-inducible p53 system, we showed that wt p53 ex-
pression is sufficient to induce Scotin protein expression in
absence of cellular stresses. However, we noticed that Scotin
protein is constitutively expressed at a basal level indepen-
dently of p53. Introduction of wt Scotin protein, but not of
mutant Scotin protein, promotes apoptosis in a caspase-
dependent manner in tumor cells devoid of p53. Inhibition
of endogenous Scotin protein expression by AS reduced
strongly, but not completely, the p53-dependent apoptosis
induced by UV irradiation, suggesting that other proapop-
totic pathways were activated. The generation of knockout
mice for the Scotin gene will help to understand the contribu-
tion of the Scotin gene in p53-dependent apoptosis and
whether loss of Scotin gene contributes to carcinogenesis.
Endogenous Scotin protein is localized in the ER in pri-
mary and in tumor cells. After transfection, Scotin is de-
tected in the ER and in the nuclear envelope, but not in the
Golgi apparatus (unpublished data) or the mitochondria.
The fact that the endogenous Scotin protein is localized in
the ER suggests that Scotin may trigger apoptosis from the
ER, although we cannot rule out that a very small fraction of
Scotin proteins, undetectable by immunostaining, can be lo-
cated in other cellular compartments. Our results with trun-
cated forms of Scotin proteins indicate that the proline-rich
domain of Scotin is required for the localization of Scotin in
the ER, whereas the NH2-terminal domain is dispensable.
We have not studied further the  pro Scotin mutant as
 100 amino acids were deleted, the lack of cytotoxicity of
this mutant (unpublished data) could be due to the loss of
the ER localization or due to the deletion of an active do-
main. Further study of the proline domain will be needed to
characterize the element(s) responsible for the localization of
Scotin in the ER and to determine whether the localization
of Scotin in the ER is required for its proapoptotic activity.
Evidence is emerging that the ER plays a major role in
apoptosis (Ferri and Kroemer, 2001). As a protein-folding
compartment, the ER is exquisitely sensitive to alterations in
homeostasis that disrupt ER functions. ER stresses include
ER calcium store depletion, inhibition of glycosylation, re-
duction of disulfide bonds, overexpression of mutant pro-
tein or protein subunits, expression of viral proteins, TNF 
treatment, and hypoxia (for review see Kaufman, 1999).
Sustained elevation of cytosolic [Ca
2 ] can induce cell death
by apoptosis. The release of calcium from the ER upon
proapoptotic signaling or after drug treatment triggers the
opening of the calcium-sensitive mitochondrial permeability
transition pore (PTP), allowing the release of cytochrome c
from the mitochondria to the cytosol. The cytosolic cyto-
chrome c binds Apaf-1 and procaspase-9, leading to caspase-9
activation, which processes and activates other caspases to
orchestrate the programmed cell death (for review see Green
and Reed, 1998). Whether Scotin can promote apoptosis in
response to ER stress remains to be determined.
The human Scotin gene maps to chromosome 3p21.3, a
region highly susceptible to aberrant chromosomal rear-
rangements and deletion in human cancer (Mitelman et al.,
1997). The very frequent loss of not only one allele of chro-
mosome arm 3p in both small lung cancer and nonsmall cell
lung cancer (Kok et al., 1987; Naylor et al., 1987), but also
in many types of human cancers such as breast, uterine and
cervical carcinoma, renal cell carcinoma, ovarian, head and
neck, and pancreatic islet cell carcinoma provides strong evi-
dence for the existence of tumor suppressor genes in this
chromosome region (Kok et al., 1997; Mitelman et al.,
1997). Therefore, future studies will determine whether mu-
tations of the Scotin gene occur in tumors and whether the
Scotin gene is a bona fide tumor suppressor gene. In sum-
mary, Scotin displays all the characteristics expected of a
gene that can contribute to p53-dependent apoptosis. The
discovery of Scotin brings to light a role of the ER in p53-
dependent apoptosis.
Materials and methods
Cell culture and cellular stress
All cell lines were purchased from American Type Culture Collection ex-
cept p53
 /  and p53
 /  MEF. All cell lines except H1299 cells were main-
tained at 37 C, 5% CO2 in DME supplemented with 10% heat-inactivated
FCS. The H1299 cell line, a human lung carcinoma cell line devoid of
p53, was routinely maintained at 37 C, 5% CO2 in RPMI 1640 medium
supplemented with 10% FCS.
H1299Tetwtp53 was derived from H1299 cells that were stably trans-
fected with a tetracycline-inducible vector encoding for wt human p53
(Gossen et al., 1995). H1299Tetwtp53 was maintained at 37 C, 5% CO2 in
DME supplemented with 10% inactivated FCS, 0.4 mg/ml G418, 0.2 mg/
ml hygromycin, and 0.5  g/ml anhydrotetracycline. To induce p53 expres-
sion, cells were incubated with fresh medium containing no anhydrotetra-
cycline. H1299Tetwtp53 cells were a gift from Dr. L. Debussche (Aventis,
Vitry-sur-Seine, France). SaosTetwtp53 and SaosTetmutp53, a gift from Dr.
C. Midgley (University of Dundee, Dundee, UK), were derived from Saos-2
(human osteosarcoma cell lines devoid of p53) that were stably transfected
with a tetracycline-inducible vector encoding for wt or mutant His169
mouse p53. Cells were routinely maintained at 37 C, 5% CO2 in DME sup-
plemented with 10% FCS and 0.5 mg/ml G418. To induce p53 expression,
cells were incubated with fresh medium supplemented with 0.5  g/ml an-
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Cells expressing the Scotin AS were derived from NIH3T3 cells that
were stably transfected with Scotin AS expression vector. Cells expressing
the control AS vector were derived from NIH3T3 cells that were stably
transfected with pcDNA3 expression vector. We used the pcDNA3 expres-
sion vector as a negative AS control because it contains, between the CMV
promoter and the poly(A)
  signal, a noncoding sequence of 100 bp not ho-
mologous to any known genes. Both cells lines were selected for 3 wk in
DME supplemented with 10% FCS and 1 mg/ml G418. Actinomycin D
and UV-C (20 J/m
2) treatments were performed as described previously
(Blattner et al., 1999).
Differential display, RT-PCR and Northern blot
p53
 /  mice and p53
 /  mice littermates were exposed for 1 min to 5 Gy
of whole body  -irradiation in a 
137Cs  -irradiator (model IBL 437C; CIS-
US, Inc.). Spleen and thymus were resected 3 h after irradiation. After total
RNA extraction, differential display was performed using the Delta™ RNA
Fingerprinting kit (CLONTECH Laboratories, Inc.). Northern blot analysis
was performed as described previously (Deguin-Chambon et al., 2000).
The cloned differentially expressed fragments and a 1.3-kb PstI cDNA frag-
ment corresponding to the rat GAPDH gene were used as radiolabeled
probes for Northern blot analysis. Semi-quantitative RT-PCR analysis was
performed using a poly-dT primer and the AMV reverse transcriptase,
followed by PCR incorporating [
33P]dCTP and using the mouse Scotin
primers 5 -GCTGTATAGAGGGCCACATGTGTTCACT-3  and 5 -AAAG-
ACAGTGCAGGGAGAAACCAGAGTG-3 , or the mouse GAPDH primers
5 -TGGACTGTGGTCATGAGCCC-3  and 5 -CAGCAATGCATCCTG-
CACC-3 . Scotin and GAPDH PCR products were analyzed on 8% PAGE/
0.5% TBE before autoradiography.
In situ hybridization
One wt male mouse and one p53
 /  male mouse were  -irradiated (5 Gy).
Spleens and thymus from untreated or treated mice were removed 3 h after
radiation. Cryosections of spleen and thymus were fixed in 4% paraformal-
dehyde in PBS, washed in sterile PBS, and dehydrated. The AS–digoxige-
nin-labeled Scotin RNA was produced by T7 RNA polymerase. As a nega-
tive control, the sense digoxigenin-labeled Scotin RNA was produced by
SP6 RNA polymerase. Sections were hybridized overnight at 60 C with
digoxigenin-labeled Scotin RNA probe. After washing at 55 C in solution A
(50% formamide, 2  SSC, 0.1% Tween 20), sections were washed in TBS,
blocked for 1 h at RT with 10% FCS in TBS, and incubated overnight at
4 C with an antidigoxigenin antibody conjugated to alkaline phosphatase
(Roche Molecular Biochemicals). The sections were washed with TBS and
hybridized probe was revealed by hydrolysis of phosphatase substrate
NBT/BCIP (Sigma-Aldrich).
Electrophoretic mobility shift assay
The binding of p53 to a DNA fragment derived from the promoter of Scotin
was analyzed by EMSA as described previously (Bourdon et al., 1997). The
potential p53-binding site S1 derived from the Scotin promoter 5 -TGT-
GTGGCCTTGTTAGGAACTTTGTCC-3  and the mutant version of S1 5 -
CCGTTCCCTGGAATTCTTAGGAACTTTGTCC-3  were used as indicated.
Point mutations are underlined.
Plasmids
The mouse Scotin cDNA was amplified from mouse thymus total RNA us-
ing the primers 5 -CGGCCGGGGCGGGGCAAG-3  and 5 -CCCGG-
GAAGGACAGTGACATC-3  in the 5 /3  RACE PCR kit (Roche Molecular
Biochemicals). The human Scotin cDNA was amplified from human pla-
centa mRNA using the primers 5 -GGTGGACAGGAGCCCTGCTCACCT-
3  and 5 -ATCACTGAGGCTGTGGCGGCACTGC-3  in the 5 /3  RACE
PCR kit. These sequence data are available from GenBank/EMBL/DDBJ un-
der accession nos. AF520698, AF520699, AF520702, and AF520703.
Mouse Scotin expression vector (AdScotin) is a mouse Scotin expression
vector plasmid driven by the minimal adenovirus major late promoter (Ad).
The plasmid AdScotin-FLAG was generated by PCR to add in frame the
FLAG peptide to the carboxyl end of Scotin (AdScotin-FLAG). SVScotin is a
mouse Scotin expression vector plasmid driven by the SV-40 early promoter.
The PCR products containing the 5 UTR of mouse Scotin or the sig-
nal sequence were amplified from plasmid AdScotin-FLAG using the
primer 5 -ACGACGTTGTAAAACGACGGCCAGAGAA-3  with either the
primer 5 -AGGCCGCGGGCGCAGCCATG-3  or the primer 5 -CAGAC-
CGCGGGGATCGAATT-3 . The SacII site present in the mouse Scotin
cDNA was used to clone both PCR products into the plasmid AdScotin-
FLAG to generate plasmids Ad N and Ad Cys. The mutant deleted of the
proline/tyrosine domain was made by PCR from AdScotin plasmid using
the primers 5 -TATGTCAGGGTTCGGAGCGACCGTCGCCATTGG-3  and
5 -CGCGCTCGAGCTACTTGTCATCGTCGTCCTTGTAATCCAGACAG-
CAG-3 . The BstXI site present in the mouse Scotin cDNA was used to
clone the PCR product into the plasmid SVScotin to generate the plasmid
SV pro.
The mouse Scotin promoter (2,900 bp; GenBank/EMBL/DDBJ accession
nos. AF520700 and AF520701) was obtained by genome walking PCR
(GenomeWalker™ PCR kit; CLONTECH Laboratories, Inc.) using the
primer 5 -CTCATTCCAGAGACAGCTAGGGGAAGTG-3 , and then the
primer 5 -CCTCCAGGTAACTGCTCACCCTGGCTCA-3 . The luciferase
reporter plasmid driven by the mouse Scotin promoter (Scot-luc) was gen-
erated by cloning the mouse Scotin promoter into the promoter-less plas-
mid pGL3-basic (Promega). The pAdluc plasmid is a luciferase expression
vector driven by the Ad promoter (Bourdon et al., 1997). The Scot-Adluc
plasmid is composed of a fragment of 760 bp derived from the mouse Sco-
tin promoter containing the p53-binding site and cloned upstream from
the minimal promoter Ad. The Mut-Adluc plasmid contains the fragment
of 760 bp mutated by PCR in 1 bp of the p53-binding site using the primers
5 -CCTTGTTAGGAACTTTCTCCCACATTGAGG-3  and 5 -CCTCAAT-
GTGGGAGAAAGTTC CTAACAAGG-3  (mutation underlined).
The plasmid SVp53 is an expression vector of human wtp53 driven by
the SV-40 early promoter (Nylander et al., 2000). The plasmid SVRenilla
was purchased from Promega (pRL-SV-40 vector). The PCR product ampli-
fied from plasmid Ad-Scotin using the primers 5 -GCCCTCGAGCCTC-
CGGGTGCCCATG-3  and 5 -GCGGAATTCGCGGGGGTGGAAAAT-
CTG-3  was cloned in the AS orientation into the pcDNA3 expression
vector to generate the mouse Scotin AS plasmid (pScot-AS). All constructs
were checked by sequencing.
Luciferase reporter assay and transfection
10
4 H1299 cells seeded per well of a 96-well plates were transfected in
triplicate by calcium phosphate precipitate containing 1  g/ml of lu-
ciferase reporter plasmid (Scot-luc, Scot-Adluc, Mut-Adluc, or PG13), 20
ng/ml of SV-Renilla luciferase (internal control), and increasing concentra-
tion of SVp53 as indicated in the legend (Fig. 2, C and D). For each trans-
fection mix, the concentration of SV-40 promoter was balanced to 0.7  g/
ml with SV-40 empty expression vector, and the total DNA concentration
was balanced to 20  g/ml with pBS plasmid (Stratagene). Cells were incu-
bated for 36 h at 37 C, washed, and lysed by adding 20  l/ well of passive
lysis buffer (Promega). The 96-well microplates were analyzed in a lumi-
nometer (MicroLumat LB96V; EG&G Berthold) using the Dual-Luciferase
®
Reporter Assay System (Promega).
FACScan™ analysis 
8   10
5 H1299 cells were seeded in a 10-cm petri dish and transfected us-
ing calcium phosphate precipitate. After 48-h incubation at 37 C, cells
were fixed in 70% ethanol and immunostained for Scotin or p53. DNA
was stained by propidium iodide. Cells were analyzed by flow cytometry
(FACScan™; Becton Dickinson) using a three-parameter analysis (Deguin-
Chambon et al., 2000). Experiments with  2% transfection efficiency
were discarded.
Caspase activity assay
The caspase-3 activity was determined 48 h after transfection using the
Colorimetric Caspase-3 Cellular Activity Assay kit (Calbiochem). In all ex-
periments using caspase inhibitor, the Z-VAD-FMK caspase inhibitor (Cal-
biochem) was added to a final concentration of 10  M to the culture me-
dium 4 h before transfection and maintained during the cell incubation.
Western blot
After treatment, cells were scraped and washed in PBS. Proteins were ex-
tracted and analyzed as described previously (Deguin-Chambon et al., 2000).
Immunofluorescence staining
3   10
5 cells seeded on 2-well glass chamber slides (LabTek) were transfected
as described, fixed by 4% paraformaldehyde, and permeabilized with 0.1%
Triton X-100 in PBS. Cells were incubated for 1 h at RT with primary antibody
diluted in 10% FCS-DME. After washing with PBS, cells were incubated with
fluorescein (FITC)-conjugated anti–mouse or anti–rabbit IgG (Jackson Immu-
noResearch Laboratories) as appropriate and diluted in 10% FCS-DME. For
double immunofluorescence staining, secondary antibodies were tested for
minimal interspecies cross-reaction (Jackson ImmunoResearch Laboratories).
For mitochondrial staining, cells were incubated for 15 min at 37 C
with 25 nM MitoTracker
® red CMXRos (Molecular Probes), 1% final con-
centration of paraformaldehyde (diluted in PBS; pH 7.1) was added to the
culture medium, and the cells were incubated for a further 30 min at 37 C.
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Production and affinity purification of the mouse and human 
anti-Scotin antibodies
The peptide PYHESLAGASQPPYNPTYK, corresponding to the COOH end
of mouse Scotin protein, or the peptide YHETLAGGAAAPYPASQPPK, cor-
responding to the COOH end of human Scotin protein, was conjugated to
the carrier protein KLH and inoculated to a rabbit as described by Harlow
and Lane (1999). The anti-Scotin antibodies were affinity-purified using a
peptide column.
Antibodies 
The anti-p53 rabbit sera (CM1 and CM5) were described previously (Midg-
ley et al., 1992), and the anti–p53 DO-1 mouse mAb was described in
Stephen et al. (1995). The mouse monoclonal anti-gp96/GRP94 antibody
was purchased from StressGen Biotechnologies Corp. The mouse mono-
clonal antibody was purchased from Sigma-Aldrich (ANTI-FLAG
® M2).
The mouse monoclonal (F5) anti–mouse Waf antibody was purchased
from Santa Cruz Biotechnology, Inc. The mouse monoclonal anti–human
Waf antibody and IgM mouse monoclonal antiactin antibody (Actin Ab-1)
were purchased from Calbiochem.
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